Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Large Registry Finds Questionable PCI Procedures Before Surgery Remain Common

Executive Summary

Although most patients undergoing diagnostic coronary catheterization before noncardiac surgery do not have symptoms of coronary disease, about half of these patients are referred for revascularization despite the lack of evidence showing a benefit of revascularization in these patients according to data from a large national registry.

You may also be interested in...



AHA 2019: Conservative Approach Works As Well As Intervention For Stable Coronary Disease In ISCHEMIA Trial

The long-awaited results of the ISCHEMIA trial showed that patients with asymptomatic stable coronary disease get no apparent benefit from coronary intervention compared to a more conservative strategy with optimal medical management.

TCT 2017: ORBITA Ignites Controversy, Twitter Storm Over Stents, But Analysts Expect Little Impact

Results of the ORBITA trial, the first sham-controlled trial of percutaneous coronary intervention with drug-eluting stents in patients with stable angina found no difference in outcomes between the sham-control group and the group PCI-treated group. The results have triggered a lot of discussion and argument among physicians about the role of stents in stable angina patients, but securities analyst do not expect the results to have much impact on the drug-eluting stent market in the forseeable future.

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel